Eszopiclone, a Nonbenzodiazepine Sedative-Hypnotic Agent for the Treatment of Transient and Chronic Insomnia

2005

Ohayon, 1997, How a general population perceives its sleep and how this relates to the complaint of insomnia, Sleep, 20, 715, 10.1093/sleep/20.9.715

Mellinger, 1985, Insomnia and its treatment: Prevalence and correlates, Arch Gen Psychiatry, 42, 225, 10.1001/archpsyc.1985.01790260019002

Costa e Silva, 1996, Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: An overview of insomniacs and related disorders-recognition, epidemiology, and rational management, Sleep, 19, 412, 10.1093/sleep/19.5.412

Hohagen, 1993, Prevalence and treatment of insomnia in general practice. A longitudinal study, Eur Arch Psychiatry Clin Neurosci, 242, 329, 10.1007/BF02190245

Klink, 1992, Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia, Arch Intern Med, 152, 1634, 10.1001/archinte.152.8.1634

Ancoli-Israel, 1999, Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I, Sleep, 22, S347

McCall, 2004, Sleep in the elderly: Burden, diagnosis, and treatment, Prim Care Companion J Clin Psychiatry, 6, 9, 10.4088/PCC.v06n0104

Schramm, 1995, Mental comorbidity of chronic insomnia in general practice attenders using DSM-111-R, Acta Psychiatr Scand, 91, 10, 10.1111/j.1600-0447.1995.tb09735.x

Roth, 2001, Consensus for the pharmacological management of insomnia in the new millennium, Int J Clin Pract, 55, 42, 10.1111/j.1742-1241.2001.tb10973.x

National Sleep Foundation

Epstein, 2002, Insomnia, Nurs Clin North Am, 37, 611, 10.1016/S0029-6465(02)00028-2

Sateia, 2000, Evaluation of chronic insomnia. An American Academy of Sleep Medicine review, Sleep, 23, 243, 10.1093/sleep/23.2.1l

Lichstein, 2000, Secondary insomnia, 297

Culebras, 1992, Update on disorders of sleep and the sleep-wake cycle, Psychiatr Clin North Am, 15, 467, 10.1016/S0193-953X(18)30250-8

Buysse, 1991, Drugs affecting sleep, sleepiness and performance, 249

Obermeyer, 1996, Effects of drugs on sleep, Neurol Clin, 14, 827, 10.1016/S0733-8619(05)70287-5

Kupfer, 1997, Management of insomnia, N Engl J Med, 336, 341, 10.1056/NEJM199701303360506

Buysse, 1994, Diagnostic concordance for DSM-IV sleep disorders: A report from the APA/NIMH DSM-IV Field Trial, Am J Psychiatry, 151, 1351, 10.1176/ajp.151.9.1351

Shapiro, 1993, ABC of sleep disorders Impact and epidemiology of sleep disorders, BMJ, 306, 1604, 10.1136/bmj.306.6892.1604

Ford, 1989, Epidemiologic study of sleep disturbances and psychiatric disorders. An oppor tunity for prevention?, JAMA, 262, 1479, 10.1001/jama.262.11.1479

Katz, 1998, Clinical correlates of insomnia in patients with chronic illness, Arch Intern Med, 158, 1099, 10.1001/archinte.158.10.1099

Katz, 2002, The relationship between insomnia and health-related quality of life in pa tients with chronic illness, J Fam Pract, 51, 229

Association of Sleep Disorders Centers and the Association for the Psychophysiological Study of Sleep, 1979, Diagnostic classification of sleep and arousal disorders. 1979 First edition, Sleep, 2, 1

1998

1997

1987, 297

1994, 597

Kryger, 1999, Recognition and diagnosis of insomnia, Sleep, 22, S421

Ringdahl, 2004, Treatment of primary insomnia, J Am Board Fam Pract., 17, 212, 10.3122/jabfm.17.3.212

Hauri, 1998, Insomnia, Clin Chest Med., 19, 157, 10.1016/S0272-5231(05)70439-1

Roehrs, 2000, Transient and short-term insomnias, 624

1968

Hirshkowitz, 2004, Normal human sleep: An overview, Med Clin North Am, 88, 551, 10.1016/j.mcna.2004.01.001

Williams, 1974

Neylan, 1999, Sleep disorders, 955

Littner, 2003, Practice parameters for using polysomnography to evaluate insomnia: An update, Sleep, 26, 754, 10.1093/sleep/26.6.754

Zorick, 2000, Evaluation and management of insomnia: An overview, 615

Standards of Practice Committee of the American Sleep Disorders Association, 1995, Practice parameters for the use of polysomnography in the evaluation of insomnia, Sleep, 18, 55

AARC-APT (American Association of Respiratory Care-Association of Polysomnography Technologists) clinical practice guideline, 1995, Polysomnography, Respir Care, 40, 1336

Attarian, 2000, Helping patients who say they cannot sleep. Practical ways to evaluate and treat insomnia, Postgrad Med., 107, 127, 10.3810/pgm.2000.03.935

Attarian, 2000, Helping patients who say they cannot sleep. Practical ways to evaluate and treat insomnia, Postgrad Med., 107, 33, 10.3810/pgm.2000.03.935

Attarian, 2000, Helping patients who say they cannot sleep. Practical ways to evaluate and treat insomnia, Postgrad Med., 107, 140, 10.3810/pgm.2000.03.935

Morin, 2003, Measuring outcomes in randomized clinical trials of insomnia treatments, Sleep Med Rev., 7, 263, 10.1053/smrv.2002.0274

Schenck, 2003, Assessment and management of insomnia, JAMA, 289, 2475, 10.1001/jama.289.19.2475

Buysse, 1989, The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research, Psychiatry Res., 28, 193, 10.1016/0165-1781(89)90047-4

Sateia, 2004, Identification and management of insomnia, Med Clin North Am., 88, 567, 10.1016/j.mcna.2004.01.008

Zhdanova, 2004, Advances in the management of insomnia, Expert Opin Pharmacother, 5, 1573, 10.1517/14656566.5.7.1573

Chesson, 1999, Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report, Sleep, 22, 1128, 10.1093/sleep/22.8.1128

Morin, 1999, Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review, Sleep, 22, 1134, 10.1093/sleep/22.8.1134

Smith, 2002, Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia, Am J Psychiatry, 159, 5, 10.1176/appi.ajp.159.1.5

Morin, 1999, Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial, JAMA, 281, 991, 10.1001/jama.281.11.991

Sateia, 2004, Insomnia, Lancet, 364, 1959, 10.1016/S0140-6736(04)17480-1

2000

2000

Parrino, 1996, Polysomnographic effects of hypnotic drugs. A review, Psychopharmacology (Berl), 126, 1, 10.1007/BF02246405

American Insomnia Association

Pagel, 2001, Medications for the treatment of sleep disorders: An overview, Prim Care Companion J Clin Psychiatry, 3, 118, 10.4088/PCC.v03n0303

Wysowski, 1991, Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989, Arch Intern Med., 151, 1779, 10.1001/archinte.151.9.1779

Kales, 1977, Comparative effectiveness of nine hypnotic drugs: Sleep laboratory studies, J Clin Pharmacol., 17, 207, 10.1177/009127007701700404

Kales, 1983, Sleep laboratory studies of hypnotic drugs: Efficacy and withdrawal effects, J Clin Psychopharmacol, 3, 140, 10.1097/00004714-198304000-00038

Damgen, 1999, Zaleplon displays a selectivity to recombinant GABA(A) receptors different from zolpidem, zopiclone and benzodiazepines, Neurosci Res Commun., 25, 139, 10.1002/(SICI)1520-6769(199911/12)25:3<139::AID-NRC3>3.0.CO;2-W

Curtis, 2002, Sleep disorders, 1323

Paul, 2004, Sleep-inducing pharmaceuticals: A comparison of mela tonin, zaleplon, zopiclone, and temazepam, Aviat Space Environ Med., 75, 512

Troy, 2000, Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance, J Clin Psychopharmacol., 20, 328, 10.1097/00004714-200006000-00007

2004

Georgiev, 2001, (S)-Zopiclone Sepracor, Curr Opin Invest Drugs, 2, 271

Sieghart, 1995, Structure and pharmacology of gamma-aminobutyric acid A receptor subtypes, Pharmacol Rev., 47, 181

Sieghart, 2002, Subunit composition, distribution and function of GABA(A) receptor subtypes, Curr Top Med Chem., 2, 795, 10.2174/1568026023393507

Bateson, 2004, The benzodiazepine site of the GABAA receptor: An old target with new potential?, Sleep Med., 5, S9, 10.1016/S1389-9457(04)90002-0

Blaschke, 1993, Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site, Chirality, 5, 419, 10.1002/chir.530050605

Fernandez, 1995, Clinical pharmacokinetics of zopiclone, Clin Pharmacokinet, 29, 431, 10.2165/00003088-199529060-00004

Weitzel, 2000, Zaleplon: A pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia, Clin Ther., 22, 1254, 10.1016/S0149-2918(00)83024-6

Leese, 2002, Esopiclone: Pharmacokinetic and pharmacodynamic ef fects of a novel sedative hypnotic after daytime administration in healthy subjects, Sleep, 25, A45

2005

Maier, 2003, Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing, Pharm Sci., 5, M1325

Gary, 2004, Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopi clone: A comparison of healthy non-elderly and elderly adults, Sleep, 27, A56

2004

Mack, 2003, Eszopiclone: A novel cyclopyrrolone with potential benefit in both transient and chronic insomnia, Formulary, 38, 582

Rosenberg, 2005, An assessment of the efficacy and safety of eszopiclone in the treatment oftransient insomnia in healthy adults, Sleep Med., 6, 15, 10.1016/j.sleep.2004.09.001

Zammit, 2004, Efficacy and safety of eszopiclone across 6 weeks of treatment for primary insomnia, Curr Med Res Opin., 20, 1979, 10.1185/174234304X15174

Krystal, 2003, Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, doubleblind, placebo-controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793

Roth, 2005, An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia, Sleep Med., 6, 487, 10.1016/j.sleep.2005.06.004

Erman, 2004, Polysomnographic and patientreported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia, Sleep, 27, 257

Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly pa tients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720

Erman, 2005, A dose-response efficacy and safety study of eszopiclone in the treatment of primary insomnia, Sleep, 28, A237

2005

2004, Hypnotic-eszopiclone, Manuf Chem., 75, 21

2003

Delahaye, 1990, Post marketing surveillance of zopiclone: Interim analysis on the first 10,000 cases in a clinical study in general practice, Int Clin Psychopharmacol., 5, 131

Powchik, 2001, (S)-Zopiclone: An isomerically pure non-benzodiazepine hypnotic without respiratory depression, Sleep, 24, A170

Caron, 2004, Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin, Sleep, 27, 55

Maier, 2004, Evaluation of pharmacokinetic and pharmacodynamic interactions between eszopiclone and warfarin, Sleep, 27, 56

Chavez, 2005, Eszopiclone (Lunesta): A new non-benzodiazepine sedative-hypnotic, P&T, 30, 388

Ozminkowski, 2005, Forecasting the impact of adding a new drug on formulary using medical claims data and clinical literature: A case study of insomnia treatment, Value Health, 8, 323, 10.1016/S1098-3015(10)62844-6